Pharma Pulse 7/9/25: J&J Aims to Reduce Oncology Care Gaps Through Community Support and Seamless Transitions; Obsolete Trial Marketing Guidelines and Missing Processes Hurt Patient Enrollment

J&J Aims to Reduce Oncology Care Gaps Through Community Support and Seamless Transitions

In an interview with Pharmaceutical Executive, Biljana Naumovic, US President, Oncology, Johnson & Johnson Innovative Medicine, discussed how the company is working to close gaps in cancer care—identified through its Oncology Care Index—by supporting community oncologists, improving care transitions, responsibly integrating AI, and reducing provider burden across the continuum.

Obsolete Trial Marketing Guidelines and Missing Processes Hurt Patient Enrollment

In an Applied Clinical Trials article, Christine Senn, PhD, FACRP, SVP, site-sponsor innovation, Advarra, outlines how outdated FDA advertising guidelines, rigid sponsor processes, and the lack of clear protocols for site-initiated materials are hindering patient recruitment in clinical trials—arguing that modern, flexible, and collaborative marketing approaches are urgently needed to improve enrollment and accelerate research.

Q&A: How Iowa PBM Bill is Set to Preserve Pharmacy Access

In a recent interview with Drug Topics, Iowa State Representative Brett Barker, PharmD, explained how Senate File 383 is designed to strengthen community pharmacy access, ensure fair reimbursement, and protect patient choice—despite temporary legal hurdles—by limiting pharmacy benefit manager control and building on proven cost-saving reforms seen in other states.

Guiding Patients Through Allergy Medication Safety: Pharmacists’ Role Following FDA Warning on Cetirizine and Levocetirizine

Following a new FDA warning about rare but severe itching after stopping long-term use of cetirizine or levocetirizine, pharmacists are being called on to guide patients through safe allergy medication use by providing education on tapering strategies, recognizing withdrawal symptoms, and promoting informed decision-making to ensure safe and effective care.

Cargo Agrees to Concentra Buyout after Trial Setback, Layoffs

After severe clinical setbacks and major layoffs, Cargo agreed to be acquired by Concentra—a firm specializing in buying struggling biotech companies below cash value—to return capital to shareholders and end Cargo’s troubled efforts in cancer cell therapy development